Talking about SMA on Rare Disease Day

On Tuesday the 26th the TreatSMA team met the new generation and talked about living with rare diseases like SMA.

TreatSMA were invited to exhibit at this year’s Rare Disease Day at Royal Holloway University. The day was organised so pupils from various schools had a chance to participate in some fun activities and learn about rare diseases. During the exhibition many pupils came to our stand and asked questions about SMA, about treatment and how it works. Some went further and asked why the NHS was not supporting reimbursement. We have also been asked “How do you cope?”- which is an amazingly thoughtful question for a 13 year old!

We did our best to explain. Of course having Dawn, Lia and Vinnie there representing different types and ages was very impactful and in general pupils and their teachers were very taken by TreatSMA!

We would like to say thank you to the Organisers of this event and hope that we will be invited next year to participate once again.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more